3 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital
In this article, we will discuss the top 3 stocks to buy according to Devesh Gandhi’s SilverArc Capital.
Dicerna Pharmaceuticals Inc (DRNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | PDT Partners Peter Muller | 0 | $0 | 0% | |
| 2. | D E Shaw D. E. Shaw | 0 | $0 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 4. | Point72 Asset Management Steve Cohen | 0 | $0 | 0% | |
| 5. | AQR Capital Management Cliff Asness | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.10 | 5,000 | Officer, Director | 43,164 | 2021-08-10 | Filing | |
| $23.66 | 3,000 | Director | 6,333 | 2021-08-10 | Filing | |
| $18.06 | 10,000 | Officer, Director | 22,300 | 2020-09-01 | Filing | |
| $7.00 | 285,000 | Large Shareholder, Director | 285,000 | 2017-12-18 | Filing | |
| $3.63 | 16,500 | Officer, Director | 55,579 | 2016-11-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.94 | 24,936 | Officer | 267 | 2021-11-18 | Filing | |
| $21.06 | 21,250 | Officer | 267 | 2021-09-17 | Filing | |
| $21.47 | 1,334 | Officer | 3,222 | 2021-09-17 | Filing | |
| $21.47 | 2,056 | Officer | 4,969 | 2021-09-17 | Filing | |
| $37.38 | 8,312 | Officer | 21,517 | 2021-08-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
Hedge Funds Are Selling Dicerna Pharmaceuticals Inc (DRNA)
Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top...
Should You Now Consider Selling Your Dicerna Pharmaceuticals (DRNA) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie.
Do Hedge Funds Love Dicerna Pharmaceuticals Inc (DRNA)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Is DRNA Stock A Buy or Sell?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their...
Is DRNA A Good Stock To Buy Now According To Hedge Funds?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here.
Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.